Center for Early Detection and Interception of Solid Tumors

Centers for Early Detection and Interception

617-762-2334

The Center for Early Detection and Interception of Solid Tumors is part of Dana-Farber’s Centers for Early Detection and Interception, a new multidisciplinary clinical and research program for individuals who are at increased risk of developing cancer.

Talk with one of our experts to evaluate if the Centers for Early Detection and Interception is the right next step for you or your patient's care.

The Center for Early Detection and Interception of Solid Tumors help patients manage precursor conditions and genetic predispositions for solid tumor cancers, including gastrointestinal, gynecologic, and head and neck tumors.

Our specialized centers evaluate individuals at high risk for developing these conditions and work with patients to manage their risk of disease progression.

Our Specialty Centers and Programs

Gastrointestinal Tumors

Center for Early Detection and Interception of Gastrointestinal Tumors specializes in precursor conditions of gastrointestinal cancers — including cancers of the colon, stomach, pancreas, and esophagus. We provide individualized plans to lower your chances of developing these cancers if you are at elevated risk. We offer comprehensive evaluation for individuals with high-risk intraductal papillary mucinous neoplasms (IPMN), gastric carcinoid tumors, neuroendocrine neoplasms of the pancreas, and Barrett’s esophagus.

Gynecologic Tumors

Center for Early Detection and Interception of Gynecologic Tumors specializes in precursor conditions of gynecologic cancers and hereditary syndromes associated with elevated risk of gynecologic tumors — including ovarian, endometrial/uterine, cervical, vulvar, vaginal, and fallopian tube. We provide customized plans for individuals at higher risk of developing these cancers. We offer comprehensive evaluation for individuals with gynecological dysplasia (such as cervical dysplasia) and endometrial intraepithelial neoplasia (EIN).

Head and Neck Tumors

We specialize in precursor conditions of head and neck tumors such as non-gynecologic human papillomavirus (HPV) and oral leukoplakia.

Multi-Cancer Early Detection Clinic

Multi-Cancer Early Detection Clinic provides comprehensive diagnostic evaluations for patients with a positive multi-cancer early detection (MCED) test, such as the GRAIL Galleri test. Using a single blood sample, MCED tests screen for numerous types of cancers — including breast, cervical, colorectal, and prostate cancers.

Dana-Farber patients who have had cancer previously, and are now in remission, can request an MCED test at our clinic.

Genetic Testing, Hereditary Conditions and Syndromes

Lynch Syndrome Center

Lynch syndrome is a common and often under-diagnosed inherited condition that increases one's risk for a variety of cancers, including colon, rectal, uterine, ovarian, urinary tract, and other malignancies. The Lynch Syndrome Center provides comprehensive care for patients with Lynch syndrome including prevention trials of vaccines, studies of risk-reducing strategies and studies of novel early detection markers.

Li-Fraumeni Syndrome and TP53 Center

The Li-Fraumeni Syndrome and TP53 Center specializes in caring for people with diagnoses of LFS and with TP53+, or those who have a family history of Li-Fraumeni syndrome.

Center for BRCA and Related Genes

Mutations in BRCA1, BRCA2, and BRCA-related genes confer increased risk of certain cancers when inherited. These mutations can also be acquired by the cancers themselves. The Center for BRCA and Related Genes provides comprehensive care for patients with inherited and acquired mutations, including clinical therapeutic trials, trials of risk-reducing strategies, and studies of novel early detection markers.

Meet Our Team

Sapna Syngal, MD, MPH
Director, Center for Early Detection and Interception of Solid Tumors
Professor of Medicine, Harvard Medical School

Elizabeth O'Donnell, MD
Director, Multi-Cancer Early Detection Clinic
Assistant Professor of Medicine, Harvard Medical School